68701-22-4

Basic information

• Product Name: 2-aMino-5-isopropylbenzoic acid
• Synonyms: 2-aMino-5-isopropylbenzoic acid;5-Isopropylanthranilic acid;Benzoic acid, 2-aMino-5-(1-Methylethyl)-
• CAS NO: 68701-22-4
• Molecular Formula: C₁₀H₁₃NO₂
• Molecular Weight: 179.21572
• Mol File: 68701-22-4.mol
• Article Data: 10

Chemical Properties

• Melting Point: 84-92℃
• Boiling Point: 328.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.161±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 2.24±0.10(Predicted)
• CAS DataBase Reference: 2-aMino-5-isopropylbenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-aMino-5-isopropylbenzoic acid(68701-22-4)
• EPA Substance Registry System: 2-aMino-5-isopropylbenzoic acid(68701-22-4)

Safety Data

• Hazardous Substances Data: 68701-22-4(Hazardous Substances Data)

Usage

Chemical Properties

Class white powder

Upstream product

• 5702-74-9 N-(4-iso-propylphenyl)acetamide 
• 68748-07-2 N-<2-bromo-4-(1-methylethyl)phenyl>acetamide 
• 51605-97-1 2-bromo-4-isopropylaniline 
• 201230-82-2 carbon monoxide 
• 68701-44-0 2-cyano-4-isopropylacetanilide 
• 79069-38-8 2-(acetylamino)-5-(1-methylethyl)benzoic acid 
• 302-17-0 chloral hydrate 
• 99-88-7 4-Isopropylaniline 

Relevant articles and documents

ARYL HYDROCARBON RECEPTOR (AHR) ACTIVATOR COMPOUNDS AS CANCER THERAPEUTICS

The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of cancers, particularly cancers that exhibit elevated expression of FOXA1 and/or FOXA1 gene targets, such as certain breast, liver and/or prostate cancers, including luminal and/or ER-positive forms of breast cancer. Three previously identified adenosine receptor antagonists, CGS-15943, MRS-1220 and SCH-58261, as well as furan ring moiety-possessing derivatives of CGS-15943 are specifically provided for killing cancer cells in a manner that appears to involve activation of the aryl hydrocarbon receptor (AHR) by such compounds. The instant disclosure therefore provides for selecting and/or administering CGS-15943, MRS-1220, SCH-58261 and/or a furan-possessing derivative of CGS-15943, MRS-1220 and/or SCH-58261 as a therapeutic agent to target a cancer cell and/or subject having or at risk of developing a cancer. Methods and compositions for therapies that include such compounds are also provided

QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES

This invention relates to quinazoline derivatives, processes for their preparation, pharmaceutical compositions, and their use in therapy of disorders in which the modulation of toll - like - receptors is involved.

Sulfonamides having antiangiogenic and anticancer activity

Compounds having methionine aminopeptidase-2 inhibitory (MetAP2) are described. Also described are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating